Health Canada has strengthened its drug and medical device shortage framework. On June 17, 2026, the department published amendments to the Food and Drug Regulations and the Medical Devices Regulations. The changes expand the government’s authority to monitor supply disruptions and respond to them faster.
For companies that manufacture, import, or distribute drugs and medical devices in Canada, the updated drug and medical device shortage framework brings real operational change. Some obligations apply right away. Others phase in over the next year. Businesses need to know which rules affect them and when.
Expanded Authority Over Drug Shortages
Health Canada’s shortage rules have historically covered a narrow set of products. Prescription drugs, controlled substances, biologics, and certain supervised non-prescription drugs made up most of the list. That list can now grow.
The amendments let Health Canada add other drugs to the shortage framework when a shortage could put patients at risk. No further regulatory change is needed once a drug is added. This gives the department more flexibility, though it does not immediately expand reporting duties for products outside the current scope.
Manufacturers of products not yet covered should still pay attention. If Health Canada decides a shortage risk exists, those products could be brought into the drug shortage notification requirements in Canada with little warning.
New Tools to Manage Shortages
Two other changes give Health Canada more room to respond once a shortage hits.
The first addresses drug expiry dates. Health Canada can now extend the expiry date of specific drug lots during a shortage. This applies only when there is solid evidence that the product will remain safe and effective for the extended period. Manufacturers seeking this option should expect to provide stability and quality data to support the request.
The second change strengthens the exceptional importation framework. This allows certain foreign-authorized drugs and devices to enter the Canadian market when domestic supply cannot meet demand. Health Canada now has more flexibility to use this tool, which may matter most in therapeutic areas already prone to disruption.
A New Reporting Requirement for Dormant Drugs
The amendments also close a reporting gap. Manufacturers must now notify Health Canada if a drug has gone unsold in Canada for twelve straight months.
This twelve-month non-sale notification is meant to catch products that have quietly left the market without a formal discontinuation filing. It should also help surface dormant DIN reporting cases, where a drug identification number stays active despite little or no recent commercial activity.
Companies should treat this as a reason for reviewing their product portfolios. A drug sitting unsold for a year now carries a specific compliance obligation, even if no one at the company has flagged it as discontinued.
Medical Devices Face a Delayed Compliance Date
Not every part of the drug and medical device shortage framework takes effect immediately. The medical device provisions follow a separate timeline.
These changes will not come into force until June 17, 2027. Until then, current medical device shortage reporting in Canada stays the same. Device manufacturers, importers, and distributors get roughly a year to prepare before the new obligations apply.
That runway is useful, but it is not long once internal processes are factored in. Companies that wait until early 2027 to start planning may find themselves short on time.
What This Means for Your Business
Companies holding drug identification numbers or medical device licences should not treat this as a wait and see situation. The twelve-month non-sale rule already applies. A portfolio review now can catch dormant products before they become a compliance issue.
Medical device companies have more time, but the 2027 deadline is closer than it looks. Building supply chain visibility and reporting workflows takes months, not weeks. Starting early gives teams room to test their processes before enforcement begins.
Firms without a global regulatory affairs team in place may find this transition harder to manage alone. Quality Smart Solutions’ regulatory compliance advisory services can help companies assess where gaps exist before they become deadlines missed.
Frequently Asked Questions
Do the new medical device shortage reporting rules apply right now?
Not yet. The medical device provisions do not take effect until June 17, 2027. Current reporting rules for devices remain in place until that date, so no immediate action is legally required, though early preparation is worthwhile.
What counts as a dormant drug under the new twelve month rule?
A drug qualifies once it has gone unsold in Canada for twelve consecutive months, even without a formal discontinuation decision. Manufacturers must notify Health Canada within a set window once that threshold is reached, which makes routine portfolio audits more important than before.
Does the expanded shortage authority mean more drugs are covered today?
Not automatically. Health Canada now has a mechanism to add drugs to the shortage framework in the future. Until a specific drug is added, current drug shortage notification requirements in Canada remain unchanged for that product.
Key Takeaways
- Health Canada published amendments to the drug and medical device shortage framework on June 17, 2026.
- Health Canada can now add more drugs to the shortage framework when risk to human health is identified.
- A new rule allows expiry date extensions for specific drug lots during shortages.
- Manufacturers must report drugs that have gone unsold in Canada for twelve months.
- Medical device shortage reporting changes do not take effect until June 17, 2027.
Next Steps
The updated drug and medical device shortage framework signals a more active approach from Health Canada. Reporting expectations are tightening for drugs now, and a clear deadline is set for medical devices next year.
Companies that start reviewing their processes today will be in a stronger position when full enforcement arrives. To assess how these changes affect your product portfolio, contact Quality Smart Solutions and speak with a regulatory specialist about your specific reporting obligations.
